| Asciminib Treatment Optimization in ≥ 3rd Line CML-CP (NCT04948333) | Novartis Pharmaceuticals | 2021-10-13 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (NCT04904588) | Center for International Blood and Marrow Transplant Research | 2021-09-30 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (NCT05088356) | Stanford University | 2021-09-07 |
| TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients (NCT05434312) | Shenzhen TargetRx Co., Ltd. | 2021-03-29 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy (NCT04014764) | Notable Labs | 2019-12-15 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411) | Masonic Cancer Center, University of Minnesota | 2019-01-02 |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. (NCT03578367) | Novartis Pharmaceuticals | 2018-11-22 |
| Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (NCT03625388) | Hikma Pharmaceuticals LLC | 2018-11-05 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (NCT03106779) | Novartis Pharmaceuticals | 2017-10-26 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies (NCT02765997) | Masonic Cancer Center, University of Minnesota | 2017-04-01 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (NCT02743351) | Fate Therapeutics | 2016-12-20 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia (NCT02709083) | Emory University | 2016-10-01 |
| Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia (NCT03216070) | Hospital Universitario Dr. Jose E. Gonzalez | 2016-04-01 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention (NCT02592447) | H. Lee Moffitt Cancer Center and Research Institute | 2015-09-29 |
| Safety And Efficacy Of Bosutinib (NCT02501330) | Pfizer | 2015-07-01 |
| Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies (NCT02338479) | Center for International Blood and Marrow Transplant Research | 2015-03-01 |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases (NCT02145039) | Masonic Cancer Center, University of Minnesota | 2014-10-01 |
| Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (NCT02208037) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-01 |
| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention (NCT01951885) | Case Comprehensive Cancer Center | 2014-07-07 |
| A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL (NCT02081378) | Novartis Pharmaceuticals | 2014-04-24 |
| Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia (NCT02047149) | University of Massachusetts, Worcester | 2014-01-01 |
| AHN-12 Biodistribution in Advanced Leukemia (NCT01207076) | Masonic Cancer Center, University of Minnesota | 2013-12-01 |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (NCT01634217) | Masonic Cancer Center, University of Minnesota | 2013-11-08 |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor (NCT01696461) | Center for International Blood and Marrow Transplant Research | 2013-05-01 |
| Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (NCT01784068) | Novartis Pharmaceuticals | 2013-03-19 |
| Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission (NCT01901666) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2013-01-01 |
| A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients (NCT02511340) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2013-01-01 |
| Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (NCT01690520) | Nohla Therapeutics, Inc. | 2012-12-11 |
| Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+ (NCT01755325) | Junmin Li | 2012-11-01 |
| Population Pharmacokinetics of Imatinib in CML Patients in Iran (NCT02146846) | Kerman University of Medical Sciences | 2012-10-01 |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell (NCT01660607) | Stanford University | 2012-02-09 |
| Improving Blood Stem Cell Collection and Transplant Procedures (NCT01517035) | National Heart, Lung, and Blood Institute (NHLBI) | 2012-01-13 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies (NCT01474681) | Novartis Pharmaceuticals | 2012-01-09 |
| Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG (NCT01390402) | M.D. Anderson Cancer Center | 2012-01-01 |
| Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia (NCT01513603) | New York Medical College | 2012-01-01 |
| Administration of Donor T Cells With the Caspase-9 Suicide Gene (NCT01494103) | Baylor College of Medicine | 2011-11-01 |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (NCT01500161) | Texas Oncology Cancer Center | 2011-11-01 |
| Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (NCT01452334) | Bristol-Myers Squibb | 2011-11-01 |
| Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) (NCT01397734) | Beth Israel Deaconess Medical Center | 2011-09-01 |
| Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (NCT01338987) | National Cancer Institute (NCI) | 2011-04-19 |
| Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia (NCT01294618) | Hospices Civils de Lyon | 2011-03-01 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (NCT01274351) | Novartis Pharmaceuticals | 2011-01-25 |
| Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia (NCT01316250) | American University of Beirut Medical Center | 2010-08-01 |
| Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (NCT01366612) | Hackensack Meridian Health | 2010-06-16 |
| Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias (NCT01149915) | Threshold Pharmaceuticals | 2010-06-01 |
| ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies (NCT01110473) | AbbVie (prior sponsor, Abbott) | 2010-04-01 |
| Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. (NCT01130688) | University of Massachusetts, Worcester | 2010-01-01 |
| An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment (NCT00980018) | Novartis Pharmaceuticals | 2009-12-01 |
| Ondansetron Versus Aprepitant Plus Ondansetron for Emesis (NCT00954941) | M.D. Anderson Cancer Center | 2009-11-01 |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy (NCT00990587) | University Health Network, Toronto | 2009-10-01 |
| A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies (NCT01036009) | University of California, San Francisco | 2009-10-01 |
| A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) (NCT01011998) | New Mexico Cancer Research Alliance | 2009-09-01 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (NCT00975975) | Indiana University | 2009-09-01 |
| Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) (NCT00760877) | Novartis Pharmaceuticals | 2009-06-01 |
| Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (NCT00802841) | Novartis Pharmaceuticals | 2009-05-01 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (NCT00807677) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial (NCT01368523) | Novartis Pharmaceuticals | 2008-12-01 |
| Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. (NCT00739141) | Memorial Sloan Kettering Cancer Center | 2008-08-12 |
| A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies (NCT00719836) | S*BIO | 2008-08-01 |
| Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT (NCT00709592) | Virginia Commonwealth University | 2008-07-21 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |
| Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies (NCT00660920) | Ariad Pharmaceuticals | 2008-06-01 |
| INCB018424 in Patients With Advanced Hematologic Malignancies (NCT00674479) | M.D. Anderson Cancer Center | 2008-05-12 |
| PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation (NCT00866346) | M.D. Anderson Cancer Center | 2008-03-01 |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR (NCT01611298) | Robert Krance | 2008-03-01 |
| Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant (NCT00674427) | University of Pennsylvania | 2008-01-01 |
| Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias (NCT00811070) | Pfizer | 2007-12-01 |
| Investigation of the Cylex® ImmuKnow® Assay (NCT00569842) | Indiana University | 2007-11-01 |
| A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) (NCT00500006) | Merck Sharp & Dohme LLC | 2007-10-01 |
| Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (NCT00852709) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-09-01 |
| Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD (NCT00539695) | Baylor College of Medicine | 2007-06-01 |
| Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) (NCT00579111) | Baylor College of Medicine | 2007-06-01 |
| Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation (NCT00626626) | Milton S. Hershey Medical Center | 2007-05-01 |
| Intraosseous Infusion of Unrelated Cord Blood Grafts (NCT00967525) | Emory University | 2007-03-01 |
| Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) (NCT00412360) | Medical College of Wisconsin | 2006-12-01 |
| TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients (NCT00415909) | M.D. Anderson Cancer Center | 2006-12-01 |
| Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant (NCT00413270) | Novartis Pharmaceuticals | 2006-12-01 |
| Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors (NCT00580281) | Memorial Sloan Kettering Cancer Center | 2006-11-01 |
| An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia (NCT00346632) | Kyowa Kirin, Inc. | 2006-06-01 |
| Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) (NCT00285259) | Astellas Pharma Inc | 2006-01-31 |
| Rollover Study of BMS-354825 in Patients With CML and Ph+ALL (NCT01030718) | Bristol-Myers Squibb | 2006-01-01 |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies (NCT00270881) | Keio University | 2006-01-01 |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients (NCT00493181) | M.D. Anderson Cancer Center | 2005-10-01 |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS (NCT00334074) | Baylor Research Institute | 2005-08-01 |
| Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) (NCT01279473) | Novartis Pharmaceuticals | 2005-08-01 |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases (NCT00309842) | Masonic Cancer Center, University of Minnesota | 2005-07-28 |
| Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan (NCT00337454) | Bristol-Myers Squibb | 2005-07-01 |
| Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial (NCT00816114) | M.D. Anderson Cancer Center | 2005-06-08 |